Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Heart Failure, Inflammation
Interventions
Low Dose Colchicine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Obesity, Insulin Resistance, Inflammation
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Coronavirus Infection
Interventions
Colchicine, Usual Care
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Statin Adverse Reaction
Interventions
Low-dose colchicine at 0.5mg daily, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Conditions
Asthma, Lung Diseases
Interventions
Albuterol, Colchicine, Adrenal Cortex Hormones, Adrenergic-Beta Agonists
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2008
U.S. locations
7
States / cities
La Jolla, California • San Francisco, California • Denver, Colorado + 4 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Apolipoprotein CIII Reduction Via Colchicine

NCT02083510
Conditions
Hypertriglyceridemia, Gout, Pericarditis
Interventions
Colchicine
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anti-platelet Effects of Colchicine in Healthy Volunteers

NCT02140372
Conditions
Healthy
Interventions
Colchicine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study of Colchicine and Theophylline

NCT00983905
Conditions
Pharmacokinetics
Interventions
Theophylline, Colchicine
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Covid19 Virus Infection
Interventions
Inflammation (I), Inflammation (II), Inflammation (III), Standard of care
Dietary Supplement · Drug
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers

Post-Ablation Pericarditis Reduction Study (PAPERS)

NCT06731595
Conditions
Atrial Fibrillation, Catheter Ablation, Pericarditis
Interventions
Colchicine
Drug
Lead sponsor
St. Vincent Cardiovascular Research Institute
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Interventions
ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Peoria, Arizona • La Mesa, California • Norcross, Georgia + 11 more
Conditions
Hyperuricemia, Gout
Interventions
Arhalofenate, Febuxostat, Colchicine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study With Colchicine in Healthy Volunteers

NCT01017003
Conditions
Pharmacokinetics
Interventions
colchicine tablets
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Atrial Fibrillation
Interventions
Colchicine 0.6 mg, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Atrial Fibrillation
Interventions
Colchicine, 0.6 mg PO BID, Matching placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Gout
Interventions
Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
Active, not recruiting Phase 1 Interventional

Study to Evaluate the Safety of Colchicine

NCT05335148
Conditions
Radiation Therapy
Interventions
oral colchicine(0.6 mg) once a day
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Conditions
Familial Mediterranean Fever
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Madera, California • Bethesda, Maryland + 2 more